FDA Grants Full Approval to Pfizer-BioNTech COVID-19 Vaccine
WASHINGTON — The Food and Drug Administration on Monday granted full approval to Pfizer-BioNTech’s coronavirus vaccine for people 16 and over, making it the first to move beyond emergency use status in the United States.
The approval comes as parts of the nation are fighting a surge in cases due to a combination of resistance to vaccination and the spread of the highly infectious delta variant.
The Biden administration hopes Monday’s announcement will motivate at least some of the roughly 85 million unvaccinated Americans who are eligible for shots to get them.
“The FDA’s approval of this vaccine is a milestone as we continue to battle the COVID-19 pandemic,” said Acting FDA Commissioner Janet Woodcock in a written statement.
“While this and other vaccines have met the FDA’s rigorous, scientific standards for emergency use authorization, as the first FDA-approved COVID-19 vaccine, the public can be very confident that this vaccine meets the high standards for safety, effectiveness, and manufacturing quality the FDA requires of an approved product,” she continued.
“While millions of people have already safely received COVID-19 vaccines, we recognize that for some, the FDA approval of a vaccine may now instill additional confidence to get vaccinated. Today’s milestone puts us one step closer to altering the course of this pandemic in the U.S.,” Woodcock added.
Pfizer said Monday that it presented the FDA with data from 44,000 clinical trial participants in the United States, as well as in the European Union, Turkey, South Africa and South America.
The company said the data showed the vaccine was 91% effective in preventing infection — a slight drop from the 95% efficacy rate that the data showed when the agency decided to authorize the vaccine for emergency use in December.
Pfizer said the decrease reflected the fact that researchers had more time to catch people who became infected.
The Pfizer-BioNTech vaccine will continue to only be authorized for emergency use for children ages 12 to 15 until Pfizer collects the necessary data required for full approval.
A decision on whether to authorize the vaccine for children younger than 12 is likely to be at least several months away.
So far, more than 92 million Americans — 54% of those fully inoculated — have gotten Pfizer shots. The majority of the rest received Moderna’s vaccine.
“We have not lost sight that the COVID-19 public health crisis continues in the U.S. and that the public is counting on safe and effective vaccines. The public and medical community can be confident that although we approved this vaccine expeditiously, it was fully in keeping with our existing high standards for vaccines in the U.S.” said Peter Marks, M.D., Ph.D., director of FDA’s Center for Biologics Evaluation and Research, in a written statement.
A poll released in June by the Kaiser Family Foundation, which has been tracking public attitudes during the pandemic, found that three of every 10 unvaccinated people said that they would be more likely to get vaccinated with a shot that had been fully approved.
In The News
ATLANTA, Ga.-- Dr. Rochelle Walensky made an unusual break Friday from a U.S. Centers for Disease Control and Prevention advisory... Read More
ATLANTA, Ga.-- Dr. Rochelle Walensky made an unusual break Friday from a U.S. Centers for Disease Control and Prevention advisory panel by overruling its guidance on booster doses for the Pfizer/BioNTech's COVID-19 vaccine. The Advisory Committee on Immunization Practices approved the boosters Thursday for anyone 65... Read More
WASHINGTON (AP) - President Joe Biden on Friday urged those now eligible for COVID-19 booster shots to get the added... Read More
WASHINGTON (AP) - President Joe Biden on Friday urged those now eligible for COVID-19 booster shots to get the added protection a day after the Centers for Disease Control and Prevention endorsed the doses for millions of older or otherwise vulnerable Americans. Opening a major new... Read More
The Centers for Medicare and Medicaid Services is disbursing an initial amount of $2 million to four health care entities... Read More
The Centers for Medicare and Medicaid Services is disbursing an initial amount of $2 million to four health care entities in four states to bolster access to their services in underserved communities. Funds will be distributed to participating hospitals in rural areas to overhaul their health... Read More
WASHINGTON -- A congressional panel on Wednesday examined whether the federal government’s strategy is appropriate for protecting children during the... Read More
WASHINGTON -- A congressional panel on Wednesday examined whether the federal government’s strategy is appropriate for protecting children during the COVID-19 pandemic. Lawmakers asked about the potential for vaccinating children, having them return safely to school and whether they should wear masks. The update they sought... Read More
WASHINGTON -- Extreme heat has played a role in worsening health outcomes, especially for minority communities and for construction and... Read More
WASHINGTON -- Extreme heat has played a role in worsening health outcomes, especially for minority communities and for construction and farm workers at risk of heat stroke. In response to rising temperatures due to climate change, the Occupational Safety and Health Administration is set to issue... Read More
WASHINGTON -- The NIH recently invested $1.67 million in five institutions to explore the link between COVID-19 vaccines and menstruation... Read More
WASHINGTON -- The NIH recently invested $1.67 million in five institutions to explore the link between COVID-19 vaccines and menstruation changes, as some women are reporting irregular or missing menstrual periods after receiving a vaccine. Only a few weeks after the NIH investment was released, an... Read More